ACADIA PHARMACEUTICALS INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value
ACADIA PHARMACEUTICALS INC. (ACAD) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value of $257.34 million as of 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue · last filed 2021-11-09
- 2021-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $257.34M.
- 2021-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $49.15M.
- 2021-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $97.42M.
- 2020-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $169.35M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value |
|---|---|
| 2021-09-30 | $257.34M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $49.15M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $97.42M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $169.35M 10-Q · filed 2021-11-09 |
| 2020-09-30 | $4.00M 10-Q · filed 2020-11-04 |
| 2020-03-31 | $114.58M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $220.83M 10-K · filed 2021-02-25 |
| 2019-09-30 | $67.03M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $4.00M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $102.19M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $242.96M 10-K · filed 2020-02-27 |
| 2018-09-30 | $96.61M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $160.37M 10-Q · filed 2018-08-08 |
| 2017-12-31 | $263.41M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |